BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Holenarsipur VK, Kandoussi H, Zeng J, Mariappan TT, Sinz M, Shen H. Detection of Weak Organic Anion–Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans. Drug Metab Dispos 2020;48:841-8. [DOI: 10.1124/dmd.120.000076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu S, Peng D, Zhu W, Liao B, Wang P, Yang D, Wu F. Hybrid_DBP: Prediction of DNA-binding proteins using hybrid features and convolutional neural networks. Front Pharmacol 2022;13:1031759. [DOI: 10.3389/fphar.2022.1031759] [Reference Citation Analysis]
2 Takubo H, Bessho K, Watari R, Shigemi R. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I. Xenobiotica 2022;:1-26. [PMID: 35638858 DOI: 10.1080/00498254.2022.2085210] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Granados JC, Bhatnagar V, Nigam SK. Blockade of Organic Anion Transport in Humans After Treatment With the Drug Probenecid Leads to Major Metabolic Alterations in Plasma and Urine. Clin Pharmacol Ther 2022. [PMID: 35490380 DOI: 10.1002/cpt.2630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Tess DA, Kimoto E, King-Ahmad A, Vourvahis M, Rodrigues AD, Bergman A, Qui R, Somayaji V, Weng Y, Fonseca KR, Litchfield J, Varma MVS. Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Clin Pharmacol Ther 2022. [PMID: 35355249 DOI: 10.1002/cpt.2593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Tang J, Shen H, Zhao X, Holenarsipur VK, Mariappan TT, Zhang Y, Panfen E, Zheng J, Humphreys WG, Lai Y. Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition. Drug Metab Dispos 2021;49:1063-9. [PMID: 34599018 DOI: 10.1124/dmd.121.000486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Neuvonen M, Tornio A, Hirvensalo P, Backman JT, Niemi M. Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans. Clin Pharmacol Ther 2021;110:1622-32. [PMID: 34580865 DOI: 10.1002/cpt.2429] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Costales C, Lin J, Kimoto E, Yamazaki S, Gosset JR, Rodrigues AD, Lazzaro S, West MA, West M, Varma MVS. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34164937 DOI: 10.1002/psp4.12672] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
8 Futatsugi A, Masuo Y, Kato Y. Effects of Probenecid on Hepatic and Renal Disposition of Hexadecanedioate, an Endogenous Substrate of Organic Anion Transporting Polypeptide 1B in Rats. J Pharm Sci 2021;110:2274-84. [PMID: 33607188 DOI: 10.1016/j.xphs.2021.02.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]